Cancer risk in women increases with height, study finds
The height study is the latest of several to report an association between postmenopausal women’s height and cancer, according to lead study author Geoffrey Kabat, a cancer epidemiologist at Albert Einstein College of Medicine in New York.
Los Angeles Times
LOS ANGELES — The taller a postmenopausal woman, the greater risk she faces of developing cancer, according to a new study.
In a paper published Thursday in the journal Cancer Epidemiology, Biomarkers & Prevention, researchers concluded that a postmenopausal woman’s cancer risk increased 13 percent with every 4 inches of height.
The study is the latest of several to report an association between women’s height and cancer, according to lead study author Geoffrey Kabat, a cancer epidemiologist at Albert Einstein College of Medicine in New York.
While it is unlikely that height in and of itself promotes cancer, the multitude of factors that influence growth — such as nutrition, genetics and environment — are likely responsible.
“Height was significantly positively associated with risk of all cancers, (including) cancers of the thyroid, rectum, kidney, endometrium, colorectum, colon, ovary and breast, and with multiple myeloma and melanoma,” the authors concluded.
The study was based on data from 144,701 women, aged 50 to 79, who participated in the Women’s Health Initiative study in the 1990s. Researchers adjusted for other potential cancer risks, such as weight, smoking, alcohol consumption and hormone therapy, as well as for frequency of cancer screening.
Researchers offered a number of possible explanations for the connection between height and cancer risk.
Height is associated with increased milk intake in childhood, and higher levels of insulinlike growth factor, which promotes cell growth and inhibits programmed cell death, the authors noted.
Increased height might also be the result of exposure to steroid hormones. Authors also noted that taller women might have larger organs and skin surface area, which may put more cells at risk of malignant growth.
“Height should thus be thought of as a marker for one or more exposures that influence cancer risk rather than a risk factor itself,” the authors wrote.
But because the study did not include men or premenopausal women, the conclusions about height are limited.
Also, the study data did not include information on leg length and sitting height — known biomarkers of growth hormone exposure.
While the current study focused only on women, other research has found an association between height and cancer among men. One study found that taller men were at slightly higher risk for aggressive prostate cancer. In May, the Journal of the National Cancer Institute reported that height differences between men and women may help explain why men have an overall greater risk of developing cancer in non-sex specific organs such as the kidneys and lungs. That study, of 65,000 men and women, showed that sex differences in height may explain a third to a half of a man’s excess cancer risk compared to women.
Material from The New York Times is included in this report.